Applied Genetic Technologies (AGTC) versus Mateon Therapeutics (MATN) Head-To-Head Contrast
Applied Genetic Technologies (NASDAQ:AGTC) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
This table compares Applied Genetic Technologies and Mateon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Applied Genetic Technologies||-88.06%||-19.77%||-16.57%|
This table compares Applied Genetic Technologies and Mateon Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Applied Genetic Technologies||$24.19 million||4.72||-$21.30 million||($1.18)||-5.34|
|Mateon Therapeutics||N/A||N/A||-$13.81 million||($0.52)||-0.35|
Mateon Therapeutics has lower revenue, but higher earnings than Applied Genetic Technologies. Applied Genetic Technologies is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings and price targets for Applied Genetic Technologies and Mateon Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Applied Genetic Technologies||0||2||3||0||2.60|
Applied Genetic Technologies currently has a consensus target price of $7.40, indicating a potential upside of 17.46%. Mateon Therapeutics has a consensus target price of $1.00, indicating a potential upside of 457.41%. Given Mateon Therapeutics’ higher possible upside, analysts plainly believe Mateon Therapeutics is more favorable than Applied Genetic Technologies.
Institutional and Insider Ownership
48.5% of Applied Genetic Technologies shares are owned by institutional investors. 5.6% of Applied Genetic Technologies shares are owned by insiders. Comparatively, 10.6% of Mateon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Applied Genetic Technologies has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500.
Applied Genetic Technologies beats Mateon Therapeutics on 7 of the 12 factors compared between the two stocks.
About Applied Genetic Technologies
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation. The company was founded in 1999 and is headquartered in Alachua, Florida.
About Mateon Therapeutics
Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical, focuses on developing small molecule injectable drugs for the treatment of cancer. It is developing CA4P, an immuno-oncology agent that stimulates the immune system against the tumor; and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.